SEC Form 4 · accession 0001562180-18-003685
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Gale Oltmans
Officer — General Counsel
Period of report
Aug 15, 2017
Accepted (ET)
Aug 17, 2018 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.94 | Aug 15, 2017 | A | 450,000 | A | — | Aug 15, 2027 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning August 15, 2018.